Attached files
| file | filename |
|---|---|
| 10-K - 10-K - FATE THERAPEUTICS INC | fate-10k_20171231.htm |
| EX-32.1 - EX-32.1 - FATE THERAPEUTICS INC | fate-ex321_9.htm |
| EX-31.1 - EX-31.1 - FATE THERAPEUTICS INC | fate-ex311_8.htm |
| EX-10.32 - EX-10.32 - FATE THERAPEUTICS INC | fate-ex1032_90.htm |
| EX-10.8 - EX-10.8 - FATE THERAPEUTICS INC | fate-ex108_147.htm |
| EX-10.5 - EX-10.5 - FATE THERAPEUTICS INC | fate-ex105_89.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statements (Form S-3 Nos. 333-199107, 333-213590, 333-215460, and 333-219987) of Fate Therapeutics, Inc., and |
|
|
2. |
Registration Statements (Form S-8 Nos. 333-191576, 333-194625, 333-202690, 333-209392, 333-211484, 333-215880, and 333-219989) pertaining to the 2007 Equity Incentive Plan, the 2013 Stock Option and Incentive Plan, 2013 Employee Stock Purchase Plan, and the Inducement Equity Plan of Fate Therapeutics, Inc.; |
of our report dated March 5, 2018, with respect to the consolidated financial statements of Fate Therapeutics, Inc. included in this Annual Report (Form 10-K) of Fate Therapeutics, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
San Diego, California
March 5, 2018